In the present disclosure, a new micro-ribonucleic acid has been developed by means of mice in which a glycine N-methyltransferase has been knocked out and high-throughput sequencing. The micro-ribonucleic acid can be used to assess whether an individual is at risk of suffering from liver diseases. Accordingly, also disclosed are primers and kits which can amplify the micro-ribonucleic acid by means of a polymerase chain reaction. Further disclosed is an inhibitor which can complement micro-ribonucleic acid and which acts as a pharmaceutical composition for treating liver diseases. Further disclosed is the in situ hybridization staining of a tissue section of an organ or tissue with the micro-ribonucleic acid to assess whether an individual is at risk of suffering from other cancers.